My Father Died From Cardiovascular Disease. I've Spent Years Studying What Happens Inside the Arteries Before the Calcium Appears

I’ve been waiting a long time to write this article. Most of my work through BiomeLogic has focused on gastrointestinal physiology, mitochondrial metabolism, immune signaling, and the relationship between microbial ecology and human disease. But cardiovascular biology has always been deeply personal to me because my father passed away from cardiovascular disease. Losing him changed the way I think about prevention, and it led me to spend years investigating the molecular processes that can develop inside our arteries long before someone experiences chest pain, a heart attack, or any recognizable symptoms.

Some time ago, I met with a physician who knew about my father’s cardiovascular history. During our discussion, he suggested that I undergo a coronary artery calcium scan, commonly called a CAC scan. He explained that a score of zero meant no detectable coronary calcium, while a score above zero indicated calcium buildup. That description was correct, but I challenged what we could conclude from it. A calcium score of zero does not necessarily mean there is no atherosclerosis. It means the scan has not detected calcified coronary plaque above its measurement threshold. Those are two very different conclusions, particularly when we are discussing someone in their 30s.

I want to be careful here because coronary calcium scoring is not an unreliable test in general. It is actually one of the better-validated imaging tools for refining cardiovascular risk in appropriately selected patients. A score of zero is associated with a substantially lower probability of cardiovascular events over the following years. But what I disagreed with was using the absence of detectable calcium as proof that the underlying disease process had never begun.

Atherosclerosis does not begin with calcium. The earliest changes generally involve the retention of cholesterol-rich lipoproteins inside the arterial wall, followed by cellular stress, inflammatory signaling, macrophage recruitment, and progressive remodeling of the tissue. Calcium can develop as the lesion evolves, but mineralization is not a prerequisite for atherosclerosis to exist.

This distinction becomes particularly relevant in younger people because plaques may be predominantly noncalcified. In the CONFIRM registry, investigators examined patients who underwent both coronary calcium scoring and coronary CT angiography. Among symptomatic patients with a CAC score of zero, approximately 13% had nonobstructive coronary disease and 3.5% had at least 50% coronary narrowing on CT angiography. That does not mean those percentages apply to healthy, asymptomatic people in their 30s. The study population was different. What it establishes is the biological and imaging limitation: the absence of detectable coronary calcium does not absolutely exclude coronary plaque.

Coronary CT angiography can visualize both calcified and noncalcified plaque and assess the arterial lumen, whereas a standard noncontrast CAC scan primarily quantifies calcification. However, I also wouldn’t recommend coronary CT angiography indiscriminately to every young person with a family history. It involves contrast, radiation exposure, and the possibility of incidental findings or unnecessary downstream testing. The correct imaging decision should depend on symptoms, estimated risk, family history, and whether the result would meaningfully change management.

There is another fascinating aspect of coronary calcium that is often overlooked. Calcium formation is not simply a process in which cholesterol gradually turns into calcium. Vascular smooth muscle cells can undergo phenotypic changes and acquire osteogenic characteristics, involving signaling networks such as BMP and RUNX2. Inflammatory signaling, extracellular vesicles, phosphate handling, cellular death, and changes in the extracellular matrix influence mineral deposition. Microscopic calcium deposits can exist below the resolution of conventional CAC imaging. Larger and denser deposits become detectable later, although the progression is heterogeneous and not every plaque follows exactly the same sequence.

Interestingly, statin therapy can sometimes increase the density of coronary calcification while reducing more lipid-rich plaque components. This is one reason an increasing calcium score during treatment does not automatically mean that the treatment is worsening atherosclerosis. Plaque composition matters. Dense calcification, microscopic calcification, lipid-rich necrotic material, and fibrous tissue do not carry identical biological implications.

To understand why I have been so focused on prevention, we have to go much deeper than calcium scoring and examine how atherosclerosis actually begins.

The first molecule I want to discuss is apolipoprotein B, or ApoB. Most people are familiar with LDL cholesterol, HDL cholesterol, and triglycerides, but ApoB is less commonly included in routine blood testing. Yet it is central to understanding how circulating lipoproteins contribute to atherosclerosis.

Cholesterol is necessary for human physiology. It contributes to cellular membrane structure, steroid hormone synthesis, and bile acid production. Because cholesterol and triglycerides are poorly soluble in the aqueous environment of blood, the body packages them into lipoprotein particles. These particles have a core containing hydrophobic lipids, a surface containing phospholipids and free cholesterol, and specific proteins that govern how they are assembled, transported, recognized, and cleared.

The liver produces very-low-density lipoproteins, or VLDL, which contain ApoB100. As VLDL circulates, lipoprotein lipase removes triglycerides, generating remnant particles and, through further remodeling, LDL. ApoB100 remains associated with the particle throughout this transformation. LDL, intermediate-density lipoproteins, VLDL remnants, and lipoprotein(a) are all important ApoB-containing particles. Intestinal chylomicrons carry ApoB48 rather than ApoB100, but fasting circulating ApoB measurements are dominated by ApoB100-containing particles.

This gives ApoB a very useful property. Each of these circulating atherogenic particles carries one structural ApoB molecule. Measuring ApoB therefore provides an approximation of atherogenic particle concentration rather than simply measuring the quantity of cholesterol transported inside them.

LDL-C and ApoB are not interchangeable. LDL-C tells us how much cholesterol is carried within the LDL fraction. ApoB tells us approximately how many atherogenic particles are circulating. Two individuals can have similar LDL-C concentrations but different ApoB concentrations because the amount of cholesterol carried per particle varies. This discordance is especially relevant in certain metabolic phenotypes, although LDL-C and ApoB are strongly correlated in the general population.

What matters biologically is that circulating ApoB-containing particles can cross the endothelial barrier and enter the arterial intima, the layer immediately beneath the endothelial cells lining the artery.

Healthy endothelium is not an impermeable wall. It actively regulates vascular permeability, nitric oxide signaling, leukocyte adhesion, coagulation, and inflammatory communication. LDL particles can enter the arterial intima even without a dramatic endothelial injury. Elevated blood pressure, smoking, disturbed blood flow, and other vascular stresses can modify the endothelial environment and increase susceptibility, but overt endothelial damage is not required for the earliest lipid retention.

Once ApoB-containing particles enter the intima, some interact with negatively charged glycosaminoglycan chains attached to arterial proteoglycans. These interactions help retain the particles within the extracellular matrix. Proteoglycans such as biglycan and versican participate in this process, and changes in glycosaminoglycan chain structure can increase lipoprotein binding.

This is the foundation of the response-to-retention model of atherosclerosis. The problem is not merely that LDL exists in circulation. It is that ApoB-containing particles can become trapped inside the arterial wall, creating the conditions for persistent local inflammation.

Retained lipoproteins may undergo oxidation, aggregation, enzymatic modification, or other structural changes. These modifications can alter how they interact with immune cells. Endothelial and vascular cells respond by increasing inflammatory mediators and adhesion molecules, including VCAM-1 and chemokines such as CCL2, which help recruit circulating monocytes into the arterial tissue.

Monocytes entering the intima can differentiate into macrophages. These macrophages express receptors capable of recognizing and internalizing modified lipoproteins, including scavenger receptors such as CD36 and SR-A1. Unlike ordinary LDL receptor uptake, some of these uptake mechanisms are not regulated by cellular cholesterol abundance in the same way. Macrophages can continue accumulating lipid as the local inflammatory environment persists.

Within the macrophage, cholesterol esters are hydrolyzed inside lysosomes, releasing free cholesterol. Excess cholesterol may be re-esterified by SOAT1, also known as ACAT1, and stored in cytoplasmic lipid droplets. When enough lipid accumulates, the macrophage develops the characteristic appearance of a foam cell.

Foam cells are among the earliest recognizable cellular features of atherosclerotic lesions. They are not simply harmless containers of fat. Their metabolic and inflammatory behavior helps determine whether a lesion resolves, progresses slowly, or develops into a more complex plaque. In addition, vascular smooth muscle cells can migrate into the intima, change phenotype, and become foam-cell-like themselves. This means that the cellular composition of atherosclerosis is more complicated than macrophages alone.

The immune system becomes increasingly involved as lipid retention persists. Modified lipoproteins, intracellular cholesterol accumulation, cell death, and cholesterol crystals can activate inflammatory signaling pathways. One of the better-characterized mechanisms involves the NLRP3 inflammasome, a multiprotein complex that promotes activation of caspase-1 and maturation of inflammatory cytokines such as IL-1β and IL-18.

IL-1β can amplify endothelial activation, leukocyte recruitment, and local inflammatory communication. IL-6 signaling can subsequently stimulate hepatic production of acute-phase proteins, including C-reactive protein. Adaptive immune cells, particularly certain T-cell populations, also influence the lesion through cytokines such as interferon-γ. The biology becomes a sustained interaction among lipoproteins, endothelial cells, macrophages, T cells, smooth muscle cells, and the extracellular matrix.

There is important human evidence that inflammation is not merely an incidental marker of this process. The CANTOS trial investigated inhibition of IL-1β in patients with established cardiovascular disease and elevated inflammatory risk. Canakinumab reduced recurrent cardiovascular events at the effective studied dose without substantially lowering LDL cholesterol. It also increased susceptibility to serious infection, illustrating why suppressing inflammation indiscriminately is not a simple preventive strategy. Nevertheless, the trial provided direct evidence that inflammatory signaling contributes causally to cardiovascular events, independently of changes in circulating LDL cholesterol.

This is where I think cardiovascular biology becomes particularly interesting. Lipid exposure and inflammation are not two competing explanations of atherosclerosis. They are interacting components of the same disease process. ApoB-containing particle retention can initiate and sustain local inflammatory signaling, while systemic inflammatory conditions, hemodynamic stress, and immune activity can influence how the arterial wall responds.

As lesions progress, some macrophages and smooth muscle cells die, releasing cellular contents and lipid into the surrounding tissue. Normally, dying cells should be cleared through efferocytosis, a process involving phagocytic receptors and signaling networks that recognize apoptotic cells. When this clearance becomes inadequate, secondary necrosis can contribute to formation of a lipid-rich necrotic core. Smooth muscle cells also produce collagen and other matrix proteins that form a fibrous cap separating thrombogenic plaque material from circulating blood.

Whether a plaque is stable depends on much more than how narrow the artery has become. A thick, collagen-rich fibrous cap can provide structural stability. A thin cap, extensive lipid-rich necrotic core, strong inflammatory activity, and increased matrix degradation may contribute to vulnerability. Proteolytic enzymes, including certain matrix metalloproteinases, can participate in degradation of the extracellular matrix. Plaque rupture exposes thrombogenic material, activating platelets and coagulation, sometimes producing an abrupt coronary thrombus and myocardial infarction. Plaque erosion is another mechanism of acute coronary thrombosis and does not require rupture of a thin fibrous cap.

An artery may also undergo outward remodeling while plaque accumulates. That means atherosclerosis can progress for years without producing substantial luminal narrowing or symptoms. This is one reason I have become skeptical of thinking about cardiovascular prevention only in terms of whether someone currently has a blockage.

My father’s death made me want to understand this process well before it reaches the point of clinical disease.

After studying the mechanisms, I began looking closely at my own blood work and genetic data. My lipid measurements from early 2026 were relatively favorable by conventional standards. My LDL cholesterol was approximately 110–117 mg/dL, HDL cholesterol was 73–81 mg/dL, and triglycerides were 49–52 mg/dL. My total cholesterol was 192 mg/dL on one of those panels, with non-HDL cholesterol of 119 mg/dL. My measured ApoB was 91 mg/dL, ApoA1 was 184 mg/dL, and the ApoB/ApoA1 ratio was approximately 0.50. My lipoprotein(a) was 35.6 nmol/L, and my previously recorded high-sensitivity C-reactive protein was below 1 mg/L.

Looking at these results, there is quite a bit that is reassuring. My triglycerides are low. My HDL is relatively high. My ApoB/ApoA1 ratio is favorable, my Lp(a) is not elevated, and my hs-CRP does not suggest a high level of systemic inflammation at the time it was measured.

But I don’t want to confuse a favorable profile with the complete absence of risk.

HDL is particularly interesting because it participates in cholesterol transport and immune regulation. ApoA1 is the major structural protein of HDL, and lipid-poor ApoA1 can interact with the ABCA1 transporter to promote cholesterol efflux from cells. More mature HDL particles participate in additional cholesterol exchange pathways, including those involving ABCG1 and SR-BI. HDL-associated enzymes and proteins may also influence oxidative and inflammatory processes.

However, HDL cholesterol concentration is not the same thing as HDL function. Having more cholesterol within HDL particles does not automatically mean that those particles are more efficient at removing cholesterol from arterial macrophages. Genetic and pharmacological studies have shown that simply increasing HDL-C does not reliably translate into fewer cardiovascular events. So although my HDL-C of 81 mg/dL is a favorable part of my lipid profile, I cannot use it as evidence that ApoB-related exposure is irrelevant.

My ApoB of 91 mg/dL is what led me to the next question. It is not an alarmingly high concentration, nor is it by itself an indication that I have cardiovascular disease. But it represents an ongoing concentration of circulating atherogenic particles, and those particles are continuously interacting with the vascular system over time.

The duration of exposure is important. Atherosclerosis is influenced by the concentration of atherogenic particles and how long the arteries are exposed to them. Someone with moderately elevated ApoB for several decades may accumulate substantial exposure even if their lipid profile never reaches the thresholds traditionally associated with severe hypercholesterolemia. This concept is supported by human genetic studies, longitudinal observational research, and randomized lipid-lowering trials, although those different forms of evidence cannot be treated as interchangeable.

For example, people who inherit genetic variants that lower LDL cholesterol throughout their lives often experience substantially lower coronary disease risk. PCSK9 loss-of-function variants helped establish this relationship. The LDLR pathway provides another line of evidence: severe impairment of LDL receptor function can dramatically increase LDL-C and accelerate atherosclerosis, while certain naturally occurring variants associated with lower LDL concentrations are linked to lower coronary risk.

This brings me to the genetics, which have been another major part of my investigation.

I previously went through whole-genome sequencing data and several reports from Nebula Genomics, focusing on genes involved in lipoprotein metabolism, vascular physiology, and longevity. Some of the variants recorded in my earlier analysis include APOE rs429358 T/T, PCSK9 rs11591147 G/G, LDLR rs6511720 T/T, LPA rs10455872 A/A, CETP rs1159806 A/T, GCKR rs1260326 C/C, CYP7A1 rs3808607 T/G, PNPLA3 rs738409 G/C, and PPARG rs1801282 C/C. I also examined SOD2 rs4880 G/G and NQO1 rs1800566 A/G in relation to redox physiology. These are previously recorded calls rather than a newly independently validated clinical genetic panel, and interpreting them requires checking the correct alleles and genomic orientation.

One of the most important genes is LDLR, which encodes the low-density lipoprotein receptor. Hepatocytes express LDL receptors on their surface to recognize and internalize LDL particles. After internalization, LDL is processed through the endosomal and lysosomal system while many LDL receptors are recycled back to the cell surface. This recycling makes hepatic LDL clearance remarkably efficient when the pathway is functioning properly. Variants affecting LDLR expression or receptor function can influence LDL concentrations and ultimately the duration of particle exposure.

My reported LDLR rs6511720 T/T genotype is especially interesting because this locus has been associated with lower LDL cholesterol and coronary risk in human genetic studies. However, an association at a common regulatory locus does not establish that my LDL receptor activity is unusually high, and the individual genotype needs to be verified before drawing a personal conclusion.

PCSK9 is another critical regulator of LDL receptor availability. PCSK9 binds to LDL receptors and favors their lysosomal degradation rather than normal recycling. Greater PCSK9-mediated receptor degradation can reduce the number of receptors available to clear LDL particles, whereas reduced PCSK9 function generally increases receptor availability and lowers circulating LDL.

One well-characterized variant is PCSK9 rs11591147, the R46L variant. The T allele is associated with reduced PCSK9 function and lower LDL concentrations. My previously recorded G/G genotype does not carry that particular protective allele. But that does not mean I have increased PCSK9 activity or a pathogenic PCSK9 mutation. It simply means that this specific loss-of-function variant was not identified in my reported genotype.

APOE is another important gene because it encodes apolipoprotein E, which participates in the hepatic clearance of triglyceride-rich remnants and broader lipid transport. APOE interacts with receptors involved in lipoprotein uptake, and different APOE isoforms influence lipid metabolism differently. My earlier reports designated me as APOE ε3/ε3, although definitive isoform assignment requires both rs429358 and rs7412 rather than rs429358 alone. The absence of APOE ε4, if confirmed, would be relevant to certain genetic risk discussions, but it would not establish protection against cardiovascular disease.

LPA is particularly important because it encodes apolipoprotein(a), which becomes covalently attached to an LDL-like particle containing ApoB100 to form lipoprotein(a), or Lp(a). Elevated Lp(a) is largely genetically determined and is associated with increased atherosclerotic cardiovascular disease and calcific aortic valve disease risk. Lp(a) also carries oxidized phospholipids, which may contribute to vascular inflammation and disease mechanisms. My reported rs10455872 A/A genotype does not carry the G allele associated with elevated Lp(a) in several studied populations, and my measured Lp(a) of 35.6 nmol/L is reassuring. Still, this single variant does not describe the entire genetic architecture of Lp(a).

CETP encodes cholesteryl ester transfer protein, which facilitates the exchange of cholesteryl esters and triglycerides among lipoprotein classes. It contributes to the remodeling of HDL and ApoB-containing particles. My reported CETP rs1159806 A/T variant is interesting in this context, but I would not interpret it as proof of particularly efficient reverse cholesterol transport. CETP biology is a good example of why having a higher HDL concentration does not automatically establish a protective mechanism.

I also examined CYP7A1, which encodes cholesterol 7α-hydroxylase, a rate-limiting enzyme in the classical pathway of hepatic bile acid synthesis. This pathway converts cholesterol into bile acid intermediates and is regulated partly through FXR, intestinal FGF19, and hepatic feedback mechanisms. CYP7A1 connects hepatic cholesterol metabolism to bile acid physiology, making it relevant to understanding cholesterol homeostasis. However, a common CYP7A1 variant does not by itself demonstrate impaired cholesterol disposal.

GCKR influences hepatic glucokinase regulation and metabolic substrate handling. PPARG regulates adipocyte differentiation, lipid storage, and insulin-responsive metabolic programs. PNPLA3 is relevant to hepatic lipid-droplet metabolism and susceptibility to fatty liver disease, particularly the rs738409 variant. My reported heterozygous PNPLA3 G/C genotype is worth understanding in the context of liver health, but it is not evidence that I currently have liver disease.

SOD2 and NQO1 were also part of my broader investigation because oxidative stress and redox regulation can influence endothelial and inflammatory physiology. SOD2 encodes mitochondrial manganese superoxide dismutase, while NQO1 participates in two-electron quinone reduction. Their biological functions are well established, but the clinical significance of individual common SNPs is much less certain. I would be cautious about claiming that my genotype at either locus predicts arterial oxidative damage or changes my need for a statin.

My longevity reports also included variants near CDKN2B-AS1 at chromosome 9p21, as well as rs12830425, rs61905747, rs4783780, rs2643826, and rs17499404. Some of these were mapped in earlier reports to loci involving longevity, immune regulation, or cardiovascular susceptibility, but several individual annotations and allele interpretations still require verification. The chromosome 9p21 region is particularly well known from coronary artery disease genetics, although the functional interpretation of one specific marker is much more complicated than simply labeling it a risk or protective gene.

The Nebula report placed my longevity-associated genetic score around the 94th percentile and my healthspan-associated score around the 73rd percentile. I find that interesting, but I don’t interpret those figures as a prediction of my lifespan. A polygenic percentile derived from selected variants is not equivalent to a validated clinical coronary risk score. Population ancestry, statistical calibration, and the number of variants included all affect how much confidence we should place in such results.

The important lesson from looking at these genes is that cardiovascular risk does not belong to one molecule or one pathway. Lipoprotein production, receptor-mediated clearance, vascular endothelial signaling, extracellular matrix biology, inflammatory activation, coagulation, and tissue repair all interact. But I also think genetics can become misleading when we force every common SNP into a mechanistic story. A plausible molecular connection is not the same as a clinically meaningful genotype effect, and an unfavorable family history should not automatically be attributed to a particular variant without evidence.

After putting all of this together, I started investigating a question that I have been reluctant to discuss publicly until now: whether starting rosuvastatin at just 5 mg daily, relatively early in life, could make sense as a long-term cardiovascular prevention strategy.

I want to emphasize that this is something I have been researching, not a treatment I am recommending to everyone and not a conclusion that I personally require medication.

Rosuvastatin inhibits HMG-CoA reductase, the enzyme responsible for converting HMG-CoA into mevalonate in the hepatic cholesterol synthesis pathway. When this pathway is inhibited, intracellular cholesterol availability decreases. The hepatocyte senses this partly through the SREBP2 regulatory system. SREBP2 promotes expression of genes involved in cholesterol homeostasis, including LDLR, increasing the liver’s capacity to remove circulating LDL particles.

The effect is not simply that less cholesterol is synthesized. It is that hepatic receptor-mediated clearance of ApoB-containing particles increases, reducing their concentration in the circulation. This is one of the major mechanisms by which statins lower LDL-C and ApoB.

What caught my attention was the potency of rosuvastatin at relatively low doses. A Cochrane systematic review found that rosuvastatin 5 mg daily reduced LDL cholesterol by approximately 41% on average across the included short-term studies. If I applied that average response to my previously measured LDL-C of 117 mg/dL, the mathematical estimate would be approximately 69 mg/dL. My actual response might differ considerably, and ApoB reduction would need to be measured separately rather than assumed to match LDL-C reduction.

Five milligrams may sound negligible, but it is not an ultralow-intensity treatment in pharmacological terms. Rosuvastatin 5 mg is classified as moderate-intensity statin therapy because it generally produces a substantial LDL-C reduction.

The hypothesis I became interested in was straightforward. If I could sustainably lower ApoB from approximately 91 mg/dL into a lower range, potentially around 60–70 mg/dL depending on the actual response, would decades of reduced circulating atherogenic particle exposure translate into meaningfully less arterial lipid retention and lower lifetime cardiovascular risk?

From a mechanistic perspective, that is a reasonable hypothesis. Fewer circulating ApoB particles should generally reduce the opportunities for particles to enter and become retained within susceptible arterial regions. Over time, lower LDL exposure reduces atherosclerotic cardiovascular risk, and there is extensive human evidence supporting the causal role of LDL-containing particles.

But here is the distinction I think matters most. Evidence that lower ApoB exposure is beneficial does not automatically prove that every otherwise healthy 34-year-old with an ApoB near 90 mg/dL should begin lifelong medication. The absolute benefit depends on the underlying probability of cardiovascular events. If that probability is very low, even a meaningful relative reduction may translate into a small absolute benefit over the next decade.

A family history of cardiovascular disease changes the discussion, but the details matter. The specific cause of my father’s cardiovascular death, the age at which disease developed, and whether other family members were affected are important for assessing inherited risk. Premature coronary disease in a first-degree relative is a particularly meaningful risk enhancer, but a family history alone does not establish that I inherited the same disease process.

There is also the issue of potential adverse effects. HMG-CoA reductase inhibition influences the broader mevalonate pathway, which produces intermediates involved in protein prenylation and CoQ10 synthesis. These pathways participate in Rho and Rac signaling, intracellular protein localization, mitochondrial electron transport, and other cellular processes. Some experimental work suggests that statins can influence endothelial signaling and inflammatory activity beyond their effects on lipoprotein concentrations. However, laboratory findings at experimental concentrations should not be treated as proof of an additional human anti-aging effect.

Statins can produce muscle symptoms in some patients, and rare severe muscle injury is possible. They can also affect certain metabolic outcomes and sometimes increase liver enzyme levels. Pharmacogenetic variation in SLCO1B1 and ABCG2 can influence rosuvastatin exposure and tolerability, so those are among the genes I would want correctly interpreted before considering long-term therapy. My previously recovered genomic information does not yet provide a complete, validated statin pharmacogenetic profile.

I have also looked at ezetimibe because it inhibits the intestinal NPC1L1 cholesterol transporter, lowering cholesterol absorption and promoting compensatory hepatic LDL clearance. It offers a different mechanism from HMG-CoA reductase inhibition, and combination approaches can sometimes produce additional LDL lowering with less statin dose escalation. But I don’t think adding medications simply to achieve increasingly low numbers is defensible without establishing that the additional reduction is likely to matter clinically.

There is now also a stronger guideline framework for thinking about the timing of prevention. The 2026 ACC/AHA multisociety dyslipidemia guideline places greater emphasis on reducing lifelong exposure to atherogenic lipoproteins. It recommends evaluating both 10-year and, where appropriate, 30-year cardiovascular risk using the PREVENT framework. For adults aged 30–59 who have low 10-year risk, LDL-C below 160 mg/dL, and 30-year ASCVD risk below 10%, lifestyle optimization is the recommended foundation. Moderate-intensity statin therapy becomes reasonable in certain higher-risk situations, including substantially elevated 30-year risk.

That is a critical point for my own investigation. My LDL-C is below 160 mg/dL, and I have not established that my calculated 30-year risk reaches a treatment threshold. I also would not assume that a coronary calcium scan is the correct next step simply because my father died from cardiovascular disease. At age 34, the chance of obtaining a zero score may be relatively high, and the result might not resolve the lifetime exposure question. The current guidelines generally emphasize selective CAC imaging in men aged 40 or older and women aged 45 or older when treatment decisions remain uncertain, rather than routine screening of all younger adults.

I keep returning to the same distinction: the absence of measurable disease today is not identical to the absence of the biological exposures that may produce disease in the future. But recognizing that distinction does not mean we should medicalize every normal variation in physiology. Good prevention requires knowing when a mechanism is clinically important enough to justify changing it.

So where does that leave my interest in rosuvastatin 5 mg?

I believe there is a scientifically credible argument for studying earlier ApoB reduction as a lifetime prevention strategy, especially in people with meaningful inherited cardiovascular susceptibility. I also believe ApoB deserves much more attention than it receives in many routine cardiovascular assessments because it connects circulating lipoprotein biology directly to the earliest stages of atherogenesis.

At the same time, my current biomarkers do not demonstrate a severe lipid disorder. My HDL, triglycerides, Lp(a), ApoB/ApoA1 ratio, and hs-CRP are reassuring in different ways. I would not dismiss those findings simply to defend a medication hypothesis. Nor would I interpret my genetic reports as proof that I need pharmacological intervention.

The unanswered question is whether my family’s history and future risk justify moving from monitoring and lifestyle-based prevention to a sustained reduction in ApoB using medication. The answer should come from a realistic assessment of absolute cardiovascular risk, verified genetics, measured biomarkers, and an honest evaluation of treatment benefits and harms.

And there is one final point I want people to understand about inflammation. My hs-CRP below 1 mg/L is reassuring as a systemic inflammatory marker, but it does not guarantee that no inflammatory process exists anywhere inside my arteries. Local immune signaling within an atherosclerotic lesion and systemic circulating inflammatory markers are related but different biological compartments. A biomarker can be useful without being capable of excluding every relevant tissue-level process.

This is why I have become increasingly interested in understanding disease before it becomes visible. Not because every microscopic process needs a medication, but because the timing of an intervention may matter as much as the intervention itself.

My father is the reason I began asking these questions. His death is not evidence that rosuvastatin is the correct answer for me, and it is not something I want to use to turn a hypothesis into a conclusion. But it is the reason I have spent so much time trying to understand the processes that lead from circulating lipoproteins to arterial retention, immune activation, foam-cell formation, necrotic plaque development, calcification, and eventually cardiovascular events.

For me, longevity research is not just about extending lifespan. It is about understanding which biological processes accumulate damage slowly enough that we fail to notice them, yet consistently enough that they eventually determine our health decades later.

The question I’m still investigating is whether reducing ApoB earlier, potentially with a carefully selected dose of rosuvastatin if the overall risk justifies it, can meaningfully change that trajectory. The mechanism is compelling, but the decision has to remain grounded in human outcomes rather than mechanistic enthusiasm.

I don’t want to wait for calcium to appear before I understand how atherosclerosis develops. But I also don’t want to confuse understanding a disease with automatically needing to treat it.

That distinction is at the center of how I approach mechanistic analysis, and it is one I wish I had understood much earlier in my life.